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IntroductIon
Hepatitis B is the most common serious liver infection in the world, with about 350 million 
people who are infected with the hepatitis B virus (HBV) and about 1 million deaths annually. 
Hepatitis B is characterized by an acute and a chronic phase, if the subject fails to produce 
adequate immune response. 
About 5-10% of adults infected with HBV go on to develop chronic infection and become 
chronic carriers (CHB); moreover, the liver damage, if not stopped, continues until cirrhosis 
or hepatocellular carcinoma. In the natural history of HBV infection, the most important event 
is HBeAg seroconversion, characterized by loss of HBeAg (a specific antigen of the virus) 
and development of anti-HBe antibodies (HBeAg-positive patients). If the seroconversion has 
occurred early (when liver damage is not already significant) and is maintained, long-term 
prognosis is excellent. The disease can follow a more aggressive course if active viral replication 
persists despite anti-HBe positivity. This state, characterized by continuing viral replication, has 
been termed as HBeAg-negative CHB, and is the most prevalent form in Italy. At the moment, 
there are 4 approved antiviral drug classes, with different antiviral efficacy, for the treatment of 
chronic hepatitis B: interferons, nucleoside analogues, nucleotide analogues, and cyclopents. 
The primary target of the treatment is a prolonged suppression of viral replication, in order to 
avoid long term complications and increase survival.
IndIcatIons and dosIng
Telbivudine is a new synthetic thymidine nucleoside analogue with selective activity against HBV; 
it is the unmodified beta-L enantiomer of the naturally occurring nucleoside thymidine. The drug 
is indicated for the treatment of chronic hepatitis B in adults with compensated liver disease, 
evidence of active viral replication and signs of liver damage. Telbuvidine is orally administred 
at a once daily dose of 600 mg. Telbuvidine is currently included by AIFA (Agenzia Italiana del 
Farmaco) in a drug efficacy and safety monitoring program.
PharmacokInetIcs
Telbuvidine pharmacokinetics data are similar in healthy subjects and CHB patients; there 
are not significant gender- or race-related differences. Dose adjustment is recommended in 
patients with moderate to severe renal dysfunction and in those undergoing hemodialysis, 
seen the prevalently renal excretion of this substance.
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absorption
Bioavailability cmax tmax Binding to plasma proteins
About 42% 3.2 ± 1.1 μg/l 3 h (1-6) 3.3 (2-5)%
metabolism and distribution
Volume of distribution metabolism metabolites
Biological activity of 
metabolites
8.2 ± 4.1 l/kg - No metabolites -
elimination
clearance Plasma terminal half-life elimination Interactions 
130 ml/min 40-49 h Primarily urinary Drugs that alter renal function
table I
Absorption, distribution, metabolism and elimination of telbivudine after oral administration
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PharmacodynamIcs
Telbuvidine is a synthetic thymidine analogue who must be activated by phosphorylation by 
cellular kinases; after activation, it selectively inhibits HBV polymerase (reverse transcriptase) 
by competing with one of its natural substrates, thymidine 5’-triphosphate.
effIcacy and safety 
Telbivudine efficacy and safety have been tested in three phase III trials, two of them using 
lamivudine as comparator, and one using adefovir dipivoxil. For the main study GLOBE, the 
vast majority of the population enrolled was asian; only 98 caucasian patients included in the 
study received telbivudine. Results showed the non-inferiority of telbuvidine over lamuvidine for 
both HBeAg-positive and negative patients; superiority of the telbuvidine treatment is showed 
only in the HBeAg-positive group. Generally, telbuvidine treatment provides greater antiviral and 
clinical efficacy than lamuvidine, with less development of resistance. Preliminary 2-year results 
show that telbivudine-treated patients exhibit higher rates of maintained responses on all key 
efficacy measures examined in both HBeAg-positive and HBeAg-negative patients populations. 
Two safety events of special interest have been identified in the GLOBAL trial: ALT flares and CK 
elevations. The first ones are globally more frequently reported in lamivudine than in telbivudine-
treated patients (13.1% vs 10.0%). CK elevations were reported with higher incidence in 
telbivudine treated patients: because the rise of this enzyme is related to muscular toxicity, 
telbivudine treatment needs a close monitoring program for muscle-related side effects.
economIc eValuatIons
Costs of currently approved products for the treatment of chronic hepatitis B can vary widely: 
factors affecting costs include the direct cost of the drug, length of treatment, and complication 
associated with continued therapy, like development of resistance or intolerable adverse events. 
study design comparator
efficacy  
(telbivudine vs lamivudine)
safety
GLOBE 
study, 2007
1,367 chronic 
hepatitis B patients 
distinguished in 
HBeAg-positive and 
negative. Double 
blind, randomized 
70-30%, multicenter, 
international phase 
III trial
Telbivudine  
600 mg daily
Lamivudine  
100 mg daily
hBeag-positive patients (n = 921) 
Therapeutic response*: 75.3% vs 67.0%  
p = 0.0049
Histologic response**: 64.7% vs 56.3%  
p = 0.0105
Showed superiority to lamivudine (52 weeks)
Incidence of adverse 
events was comparable 
between the two 
groups; AEs most 
commonly reported for 
telbivudine are infection 
and infestations, 
gastrointestinal 
disorders, general 
disorders and 
administration site 
conditions
hBeag-negative patients (n = 446) 
Therapeutic response*: 75.2% vs 77.2%  
p = 0.6187
Histologic response**: 66.6% vs 66.0%  
p = 0.8994
Showed non-inferiority to lamivudine (52 weeks)
Hou J et al., 
2008
332 chronic 
hepatitis B patients 
distinguished in 
HBeAg-positive and 
negative. Double 
blind, randomized, 
multicenter, 
international phase 
III trial
Telbivudine  
600 mg daily
Lamivudine  
100 mg daily
hBeag-positive patients (n = 290)
Reduction of serum HBV DNA: 6.3 log10 vs  
5.5 log10, p < 0.001
HBV DNA polymerase chain-reaction negative: 
67% vs 38%, p < 0.001
ALT normalization: 87% vs 75%, p = 0.007
Therapeutic response: 85% vs 62%, p < 0.001
HBeAg loss: 31% vs 20%, p = 0.047
HBeAg-negative patients (n = 42) 
Treatment effects showed similar pattern
Clinical adverse events 
were similar in the two 
treatment groups
Chan HL  
et al., 2007
135 treatment-naïve, 
chronic hepatitis 
B HBeAg-positive 
patients. Open-
label, randomized, 
controlled, phase 
III trial
(1) Telbivudine 
daily (52 weeks)
(2) Adefovir daily 
(52 weeks)
(3) Adefovir  
(24 weeks) + 
Telbivudine 
(28 weeks)
hBeag-positive patients (n = 131)
Reduction of serum HBV DNA: (1) 6.30 log10 vs 
(2)+(3) 4.97 log10, p < 0.001
HBV DNA polymerase chain-reaction negative:  
(1) 39% vs (2)+(3) 12%, p = 0.001
Mean residual HBV DNA level: (1) 3.01 log10 vs  
(2) 4.00 log10 vs (3) 3.02 log10, p = 0.004
AEs were similar across 
groups; the most 
common were upper 
respiratory symtoms, 
headache, back pain, 
diarrhea
table II
Summary of main studies investigating efficacy and safety of telbivudine in hepatitis B chronic patients
 AEs = adverse events.
 * primary endpoint, defined as serum HBV DNA < 5 log10 copies/ml associated with either HBeAg loss or ALT normalization at week 52
 ** secondary endpoint, defined as at least 2-point reduction in the Knodell necroinflammatory score with no worsening in the fibrosis 
score
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Currently there are six approved drugs for hepatitis B therapy: interferon alpha-2b, pegylated 
interferon alpha-2a, and four oral monotherapeutic agents (adefovir dipivoxil, entecavir, 
lamivudine and telbivudine). Injectable interferons and oral drugs represent two different 
pharmacological approaches, one based on host immunity stimulation, and the other on direct 
antiviral action. Furthermore, polymerase inhibitors need to be indefinitely administered since 
they are unable to induce a sustained response even after years of continuous administration. 
Costs of treatment with oral drugs represent a drastic reduction compared to subcutaneous 
therapy, and these treatments are also associated with a good response rate and excellent 
safety profile, making the overall treatment with oral drugs cost effective. The main limitation of 
these drugs is the emergence of resistance during the treatment: in particular patients treated 
with lamivudine, which is effective and not expensive, reported high resistance rates, ranging 
from 14-32% after 1 year of therapy to 58% with 2-3 years. 
In Table III we calculated the monthly pharmaceutical cost of available hepatitis B treatments 
in Italy: this is not to be intended as a cost-minimization analysis, but as a simple overlook of 
currently available treatments. Considered dosages are those derived from reference trials or 
from the SPCs of the products. For interferon alpha-2b, we considered a dosing of 9-10 MIU/3 
times a week for HBeAg+ patients and of 5-6 MIU/3 times a week for HBeAg-, as seen in a 
national treatment protocol. Prices of the drugs are deduced from Informatore Farmaceutico 
2008: we always considered ex-factory price. 
Globally, the monthly cost of telbivudine is nearly the same of entecavir (379 €), and similar to 
the one of adefovir; the cost of peginterferon is almost twice, and the less costly drug results 
lamivudine, with a monthly cost of about 54 €.
Name of the Medicinal Product Sebivo
Marketing Authorisation Holder Novartis Europharm LTD
Active Substance Telbivudine 
Pharmaco-therapeutic Group Antiviral for systemic use
ATC Code J05AF11 
Date of issue of Marketing Authorisation valid 
throughout the European Union 
24 April 2006
rs frequency Package Price 
ex-factory 
price
monthly 
price**
self-injectable drugs
Interferon alpha-2b (HBeAg+ pts) PHT 10 MIU 3 times a week 1 vial 88.46 53.60 611.03
Interferon alpha-2b (HBeAg+ pts) PHT 18 MIU 3 times a week 1 vial 147.46 89.35 565.87
Interferon alpha-2b (HBeAg+ pts) PHT 25 MIU 3 times a week 1 vial 203.69 123.42 562.78
Interferon alpha-2b (HBeAg- pts) PHT 10 MIU 4 times a week 1 vial 88.46 88.46 353.75
Interferon alpha-2b (HBeAg- pts) PHT 18 MIU 5 times a week 1 vial 147.46 147.46 327.61
Interferon alpha-2b (HBeAg- pts) PHT 25 MIU 6 times a week 1 vial 203.69 203.69 325.82
Peginterferon alpha-2a* PHT 180 mcg 3 times a week 1 vial 321.41 194.75 778.98
oral drugs
Adefovir dipivoxil* H 10 mg Daily 30 tablets 705.55 427.50 399.00
Entecavir* H 0.5 mg Daily 30 tablets 670.28 406.13 379.05
Entecavir* H 1 mg Daily 30 tablets 670.28 406.13 379.05
Lamivudine PHT 100 mg Daily 28 tablets 89.57 54.27 54.27
Lamivudine PHT 5 mg Daily Oral solution (240 ml) 38.43 23.29 54.33
Telbivudine* H 600 mg Daily 28 tablets 625.58 379.04 379.04
table III
Monthly pharmaceutical costs of different available therapies for chronic hepatitis B treatments
 * Price neglects further negotiated discounts on supplies for NHS
 ** Four weeks
 H = hospital prontuary; PHT = hospital-territorial prontuary; pts = patients; RS = reimbursement status; MIU = million international unit
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